老年新诊断急性髓系白血病强化与低强度一线治疗的选择
老年急性髓系白血病患者因疾病生物学更具侵袭性且对细胞毒化疗耐受差,结局逊于年轻患者。低强度方案(去甲基化药物联合维奈克拉)一线应用显著改善老年或不适合强化疗患者结局,但正式批准限于75岁及以上或伴临床显著合并症者。本文综述支持强化疗与低强度维奈克拉方案的前瞻性与回顾性数据,并讨论作者所在中心根据细胞分子特征选择最佳一线治疗的做法。
要点
- 老年急性髓系白血病患者因合并症或衰弱常不适合强化疗,适合者也可能出现高发病率及早期和晚期死亡。
- 去甲基化药物联合维奈克拉一线治疗显著改善老年或不适合强化疗患者的缓解率和生存。
- 该联合方案正式批准限于75岁及以上或伴临床显著合并症的患者。
核心结论
- 去甲基化药物联合维奈克拉一线治疗显著改善老年或不适合强化疗的急性髓系白血病患者的结局。
研究设计与样本
- 本文为观点(Viewpoint)文章,综述支持强化疗和低强度维奈克拉方案治疗老年急性髓系白血病患者的回顾性与前瞻性数据。
主要发现
- 老年急性髓系白血病患者结局逊于年轻患者,部分因疾病生物学更具侵袭性和对细胞毒化疗耐受更差。
- 历史上强化疗被认为是唯一有效治疗,但许多老年患者因合并症或衰弱不适合强化疗。
- 适合强化疗的老年患者仍可出现高发病率及早期和晚期死亡。
- 去甲基化药物联合维奈克拉一线治疗显著改善老年或不适合强化疗患者的缓解率和生存。
- 该联合方案正式批准限于75岁及以上或伴临床显著合并症的患者,但高缓解率和生存改善使许多执业者考虑用于无显著合并症的老年患者甚至高危特征年轻患者。
关键数值与推荐
- 去甲基化药物联合维奈克拉的正式批准限于年龄75岁及以上或伴临床显著合并症的患者。
临床怎么用
- 作者所在中心根据细胞分子特征确定老年或不适合强化疗急性髓系白血病患者的最佳一线治疗。
- 许多执业者考虑将低强度去甲基化药物联合维奈克拉方案用于无显著合并症的老年患者及高危特征年轻患者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The outcomes of older patients with acute myeloid leukaemia are inferior to their younger counterparts, because, in part, of a more aggressive disease biology and poorer tolerance of cytotoxic chemotherapy. Although intensive chemotherapy was historically considered the only effective treatment for these patients, many older patients are not suitable for intensive chemotherapy owing to comorbidities or general frailty. Determination of patient fitness for intensive chemotherapy is imperfect, and even older patients who appear to be suitable (also known as fit) for intensive chemotherapy can have high rates of morbidity and early and late mortality with this approach. Fortunately, the outcomes of older or unfit patients with acute myeloid leukaemia have substantially improved with the use of a hypomethylating agent plus venetoclax in the front-line setting. Although the formal approval of this combination is limited to patients aged 75 years or older, or those with a clinically significant comorbidity, the high response rates and survival improvement in these patients have led many practitioners to consider this low-intensity regimen in older patients without significant comorbidities and even in younger patients with high-risk disease features for whom the expected outcomes with intensive chemotherapy are poor. Modifications to the hypomethylating agent plus venetoclax backbone might further improve the outlook for these patients, particularly in some acute myeloid leukaemia subsets with a targetable mutation. In this Viewpoint, we review the retrospective and prospective data supporting both intensive chemotherapy and low-intensity venetoclax-based approaches in older patients with acute myeloid leukaemia. We also discuss our own approach to the management of older or unfit patients with acute myeloid leukaemia, including how cytomolecular features have a role in establishing the optimal front-line therapy.
引用
- Short NJ, Kantarjian H. Choosing between intensive and less intensive front-line treatment approaches for older patients with newly diagnosed acute myeloid leukaemia. Lancet Haematol. 2022. PMID: 35772432. doi:10.1016/S2352-3026(22)00167-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。